Abstract
In Reply. —It is well known that TRUS is neither sensitive nor specific in identifying prostatic cancer. Approximately one half of prostatic cancers greater than 1 cm in diameter are not visualized on TRUS and only 15% of hypoechoic lesions turn out to be cancer. 1 These observations are further confirmed by our study that demonstrated that TRUS was not predictive of whether tumor was significant or insignificant. Furthermore, investigators at the Mayo Clinic also have shown that there is no difference in tumor extent whether a lesion was visualized or not visualized on TRUS. 2 The rationale for the current TNM staging is not clear. We hope this issue will be reevaluated based on the evidence presented above, and in the future TRUS upstaging of nonpalpable lesions will be eliminated from this classification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
